Generalized Anxiety Disorder

Generalized Anxiety Disorder

Generalized Anxiety Disorder

On this page

Introduction & Epidemiology - Worry Whirlwind Basics

  • Core: Excessive, uncontrollable anxiety and worry concerning multiple everyday events or activities (e.g., work, health).
  • Duration: Occurs more days than not for at least 6 months (DSM-5 criteria).
  • Symptoms (≥3 required):
    • Restlessness/on edge.
    • Easy fatigue.
    • ↓Concentration.
    • Irritability.
    • Muscle tension.
    • Sleep disturbance.
  • Epidemiology:
    • Prevalence: Lifetime 5-9%; 12-month 3%. Notably common.
    • Gender: Females > Males (≈ 2:1).
    • Onset: Median age of onset ~30 years; typically chronic, fluctuating course.
    • Comorbidity: High with depression & other anxiety disorders.

⭐ Hallmark: Chronic, pervasive worry, difficult to control, often shifting between multiple everyday concerns, causing significant distress.

Clinical Features & Diagnosis - Spotting the Stress Storm

  • Core Feature: Persistent, excessive, uncontrollable anxiety/worry (multiple domains).
  • Duration: ≥ 6 months (more days than not).
  • Associated Symptoms (≥ 3 required; ≥ 1 in children):
    • Restlessness, feeling "keyed up"/"on edge".
    • Easy fatigability.
    • Difficulty concentrating, mind going blank.
    • Irritability.
    • Muscle tension.
    • Sleep disturbance (e.g., insomnia, unsatisfying sleep).
  • Impact: Clinically significant distress or functional impairment.
  • Exclusion: Not due to substance, medical condition, or other mental disorder.

Diagnosis:

  • Clinical diagnosis based on DSM-5 criteria.
  • Key step: Rule out other causes:
    • Other anxiety/mood disorders (e.g., Panic Disorder, MDD).
    • Medical conditions (e.g., hyperthyroidism, cardiac issues).
    • Substance use/withdrawal.
  • Screening Tool: GAD-7 (Generalized Anxiety Disorder 7-item scale).
    • Score ≥ 5: Mild.
    • Score ≥ 10: Moderate (clinically significant).
    • Score ≥ 15: Severe.

⭐ > GAD often co-occurs with Major Depressive Disorder (MDD) and other anxiety disorders.

GAD-7 Anxiety Assessment Scale

Etiology & Comorbidities - Roots & Risky Relatives

  • Genetic Factors:

    • Heritability ~30%.
    • Complex polygenic inheritance.
  • Neurobiological Factors:

    • Neurotransmitters: Imbalances: ↓ GABA, ↓ Serotonin (5-HT), ↑ Norepinephrine. Corticotropin-releasing hormone (CRH) dysregulation implicated.
    • Brain Regions: Amygdala hyperactivity (fear). Altered prefrontal cortex (PFC) & anterior cingulate cortex (ACC) activity (worry circuits).
    • 📌 Mnemonic: "Anxious GADgets have Sad Nerves & Grumble" (Serotonin↓, Norepinephrine↑, GABA↓).
  • Psychological Factors:

    • Cognitive Biases: Intolerance of uncertainty, negative problem orientation, catastrophizing.
    • Personality Traits: High neuroticism, harm avoidance.
  • Environmental Factors:

    • Chronic life stressors, childhood adversity, trauma.
  • Comorbidities:

    • High: 50-90% lifetime comorbidity with other psychiatric disorders.
    • Most Frequent: Major Depressive Disorder (MDD).
    • Other Common: Other anxiety disorders (panic disorder, social anxiety disorder), substance use disorders. ⭐ > GAD frequently precedes Major Depressive Disorder onset, a significant risk factor.

Neurobiological model of anxiety disorders

Management - Taming the Tension

  • Goal: Symptom reduction, functional improvement.
  • Core: Psychotherapy (CBT) + Pharmacotherapy (SSRIs/SNRIs).
  • Pharmacotherapy:
    • SSRIs (First-line): Escitalopram (10-20 mg/day), Sertraline (50-200 mg/day), Paroxetine.
      • Start low, titrate. Effect in 4-6 wks.
    • SNRIs (First-line): Venlafaxine XR (75-225 mg/day), Duloxetine (60-120 mg/day).
    • Buspirone: Non-sedating. Onset 2-4 wks. Augmentation.
    • Pregabalin: Anxiolytic, for somatic symptoms.
    • BZDs: (Clonazepam, Lorazepam)
      • Short-term (<2-4 wks) for acute distress. ⚠️ Dependence risk.
    • Others: Hydroxyzine, TCAs (Imipramine - less preferred).
  • Psychotherapy:
    • CBT: Gold standard. Psychoeducation, relaxation, cognitive restructuring, exposure.
    • Mindfulness-based therapies.

⭐ SSRIs (e.g., Escitalopram, Sertraline) are the first-line pharmacological agents for Generalized Anxiety Disorder, typically continued for 6-12 months after remission.

oka

High‑Yield Points - ⚡ Biggest Takeaways

  • GAD: Chronic, excessive worry (≥6 months) about multiple domains.
  • Requires ≥3 somatic symptoms (e.g., restlessness, fatigue, muscle tension, sleep issues, poor concentration).
  • First-line: SSRIs/SNRIs and Cognitive Behavioral Therapy (CBT).
  • Benzodiazepines: For short-term relief only; risk of dependence.
  • Buspirone: Non-sedating, delayed onset (2-4 weeks), good for long-term.
  • Differentiate from panic disorder (sudden attacks) & social anxiety (social phobia).
  • High comorbidity with depression and other anxiety disorders.

Practice Questions: Generalized Anxiety Disorder

Test your understanding with these related questions

A 28-year-old woman who reports being a "nervous person" and experiences chronic tension, exhibits symptoms of both sympathetic and parasympathetic nervous system activation, and has insomnia is most likely to be suffering from which condition?

1 of 5

Flashcards: Generalized Anxiety Disorder

1/9

First-line treatment for social anxiety disorder includes _____ + SSRIs or venlafaxine

TAP TO REVEAL ANSWER

First-line treatment for social anxiety disorder includes _____ + SSRIs or venlafaxine

CBT

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial